Thermo Fisher Scientific Announces More Than 30 Orders for Ion GeneStudio S5 One Week After Debut
CARLSBAD, Calif., Jan. 16, 2018 /PRNewswire/ — Thermo Fisher Scientific today announced it has received more than 30 orders for multiple Ion GeneStudio S5 Systems a week after launching the new line of benchtop next-generation sequencing (NGS) instruments. The sequencers have been purchased by early access laboratories for application areas ranging from cancer research to metagenomics.
“We are very excited to start working with the new Ion GeneStudio S5 Prime system in our lab,” said Dr. Sarah Jacobs-Helber, Ph.D., HCLD (ABB), Laboratory Director of GENETWORx, which focuses on translating the latest scientific findings into actionable knowledge to enable precision medicine. “The speed and scalability it provides will be an invaluable resource for our work in clinical research and its flexibility will enable greater cost-efficiencies with each experiment.”
The Ion GeneStudio S5 Series of instruments have been designed with end-to-end automation, including library prep, which results in lower laboratory operational costs and minimizes human errors. The systems provide the most flexibility of any NGS benchtop system on the market. Users can easily scale their experiments by switching between the interchangeable Ion S5 chips – not another sequencer – to match the appropriate throughput requirements for their application of interest.
When combined with Thermo Fisher’s breadth of assays, the best-in-class Ion AmpliSeq technology and the newly announced Ion AmpliSeq HD technology, automated sample prep platform and downstream bioinformatics and reporting tools, the entire offering delivers the industry’s most-comprehensive, end-to-end solution for targeted NGS.
“We are very proud of our customers’ immediate response to our new NGS series of instruments. It’s exciting to hear that the systems’ unmatched flexibility, speed and ability to maximize efficiency are striking a chord in the research and clinical research markets,” said Joydeep Goswami, president of Clinical Next-Generation Sequencing and Oncology for Thermo Fisher Scientific. “For fast answers to important scientific questions, no matter the scale of your targeted research, whether it is cancer or inherited disease research, microbial or infectious disease applications, this is a platform and workflow that we believe will delight customers.”
For more information on the Ion GeneStudio S5 Systems, please visit www.thermofisher.com/askgenestudio.
Ion GeneStudio S5 Systems are for research use only. Not intended for diagnostic procedures.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
Media Contact Information:
Mauricio Minotta, Thermo Fisher Scientific
+1 760 929 2456
+1 760 805 5266 (mobile)
mauricio.minotta@thermofisher.com
SOURCE Thermo Fisher Scientific Inc.